File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: [Differentiating effect of PPARgamma ligand rosiglitazone and all trans-retinoic acid on myeloma cells and its possible mechanism].

Title[Differentiating effect of PPARgamma ligand rosiglitazone and all trans-retinoic acid on myeloma cells and its possible mechanism].
Authors
Issue Date2009
PublisherChinese Medical Association
Citation
Zhonghua Zhong Liu Za Zhi [Chinese Journal Of Oncology], 2009, v. 31 n. 12, p. 885-889 How to Cite?
AbstractOBJECTIVE: To investigate the effects of PPARgamma ligand (rosiglitazone, RGZ) as well as combined with all trans-retinoic acid (ATRA) on human myeloma cells and try to explore the possible mechanism. METHODS: Human myeloma cell lines U266 and RPMI-8226 cells were treated with RGZ in the presence or absence of ATRA. Cell proliferation was evaluated by [(3)H] thymidine incorporation, cell cycle distribution and CD49e expression were analyzed by flow cytometry, morphology changes were evaluated by Wright-Giemsa staining, and p27(Kip1) and p21(Waf1) expression was detected by Western blotting. RESULTS: The exposure to RGZ induced proliferation inhibition in both cell lines in a dose-dependent manner. After cultured with 5 micromol/L RGZ, the proportion of U266 and RPMI-8226 cells in phase G(0)/G(1) was (45.2 +/- 6.7)% and (40.3 +/- 7.3)%, respectively (P < 0.05). The proportion of the cells in phase G(2)/M and S was (52.2 +/- 7.4)% and (57.4 +/- 9.5)%, respectively (P < 0.05). These changes were more evident when the RGZ concentration was increased to 10 micromol/L. A combination of RGZ with ATRA enhanced the growth inhibition and cell cycle arrest effects of RGZ. The RGZ-treated myeloma cells displayed morphological characteristics of cell differentiation, and more evident signs of differentiation were observed when RGZ was combined with ATRA. These changes were confirmed by the detection of CD49e expression. The expression of p27(Kip1) and p21(Waf1) in myeloma cells was up-regulated by RGZ and this change was more apparent when RGZ was used in combination with ATRA. CONCLUSION: RGZ can induce cell cycle arrest and cell differentiation in myeloma cells which maybe caused by up-regulation of p27(Kip1) and p21(Waf1) expression. ATRA can enhance these effects of RGZ on multiple myeloma cells and combined use of these two drugs may show a synergistic effect on myeloma cells.
Persistent Identifierhttp://hdl.handle.net/10722/125009
ISSN
2015 SCImago Journal Rankings: 0.190

 

DC FieldValueLanguage
dc.contributor.authorHuang, HWen_HK
dc.contributor.authorChen, GHen_HK
dc.contributor.authorChang, HRen_HK
dc.contributor.authorChow, HCen_HK
dc.contributor.authorLeung, AYen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorWu, DPen_HK
dc.date.accessioned2010-10-31T11:06:24Z-
dc.date.available2010-10-31T11:06:24Z-
dc.date.issued2009en_HK
dc.identifier.citationZhonghua Zhong Liu Za Zhi [Chinese Journal Of Oncology], 2009, v. 31 n. 12, p. 885-889en_HK
dc.identifier.issn0253-3766en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125009-
dc.description.abstractOBJECTIVE: To investigate the effects of PPARgamma ligand (rosiglitazone, RGZ) as well as combined with all trans-retinoic acid (ATRA) on human myeloma cells and try to explore the possible mechanism. METHODS: Human myeloma cell lines U266 and RPMI-8226 cells were treated with RGZ in the presence or absence of ATRA. Cell proliferation was evaluated by [(3)H] thymidine incorporation, cell cycle distribution and CD49e expression were analyzed by flow cytometry, morphology changes were evaluated by Wright-Giemsa staining, and p27(Kip1) and p21(Waf1) expression was detected by Western blotting. RESULTS: The exposure to RGZ induced proliferation inhibition in both cell lines in a dose-dependent manner. After cultured with 5 micromol/L RGZ, the proportion of U266 and RPMI-8226 cells in phase G(0)/G(1) was (45.2 +/- 6.7)% and (40.3 +/- 7.3)%, respectively (P < 0.05). The proportion of the cells in phase G(2)/M and S was (52.2 +/- 7.4)% and (57.4 +/- 9.5)%, respectively (P < 0.05). These changes were more evident when the RGZ concentration was increased to 10 micromol/L. A combination of RGZ with ATRA enhanced the growth inhibition and cell cycle arrest effects of RGZ. The RGZ-treated myeloma cells displayed morphological characteristics of cell differentiation, and more evident signs of differentiation were observed when RGZ was combined with ATRA. These changes were confirmed by the detection of CD49e expression. The expression of p27(Kip1) and p21(Waf1) in myeloma cells was up-regulated by RGZ and this change was more apparent when RGZ was used in combination with ATRA. CONCLUSION: RGZ can induce cell cycle arrest and cell differentiation in myeloma cells which maybe caused by up-regulation of p27(Kip1) and p21(Waf1) expression. ATRA can enhance these effects of RGZ on multiple myeloma cells and combined use of these two drugs may show a synergistic effect on myeloma cells.en_HK
dc.languagechien_HK
dc.publisherChinese Medical Association-
dc.relation.ispartofZhonghua zhong liu za zhi [Chinese journal of oncology]en_HK
dc.subject.meshCell Proliferation/drug effects*-
dc.subject.meshMultiple Myeloma/pathology*-
dc.subject.meshThiazolidinediones/pharmacology*-
dc.subject.meshTretinoin/pharmacology*-
dc.subject.meshIntracellular Signaling Peptides and Proteins/metabolism-
dc.title[Differentiating effect of PPARgamma ligand rosiglitazone and all trans-retinoic acid on myeloma cells and its possible mechanism].en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0253-3766&volume=31&issue=12&spage=885&epage=889&date=2009&atitle=Differentiating+effect+of+PPARgamma+ligand+rosiglitazone+and+all+trans-retinoic+acid+on+myeloma+cells+and+its+possible+mechanism-
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid20193324-
dc.identifier.scopuseid_2-s2.0-78049431509en_HK
dc.identifier.hkuros180385en_HK
dc.identifier.volume31en_HK
dc.identifier.issue12en_HK
dc.identifier.spage885en_HK
dc.identifier.epage889en_HK
dc.identifier.scopusauthoridHuang, HW=36609977500en_HK
dc.identifier.scopusauthoridChen, GH=36609835200en_HK
dc.identifier.scopusauthoridChang, HR=14009563100en_HK
dc.identifier.scopusauthoridChow, HC=7102303391en_HK
dc.identifier.scopusauthoridLeung, AY=36610399300en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridWu, DP=23471117100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats